Man Group plc Invests $215,000 in Delcath Systems, Inc. (NASDAQ:DCTH)

Man Group plc purchased a new position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 17,852 shares of the company's stock, valued at approximately $215,000. Man Group plc owned 0.06% of Delcath Systems at the end of the most recent quarter.

A number of other institutional investors also recently made changes to their positions in the stock. Quarry LP bought a new stake in shares of Delcath Systems in the 4th quarter worth approximately $34,000. Quantbot Technologies LP acquired a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $66,000. Boothbay Fund Management LLC raised its holdings in shares of Delcath Systems by 30.2% during the fourth quarter. Boothbay Fund Management LLC now owns 34,749 shares of the company's stock valued at $418,000 after acquiring an additional 8,061 shares during the period. Riverwater Partners LLC raised its holdings in shares of Delcath Systems by 46.2% during the fourth quarter. Riverwater Partners LLC now owns 27,229 shares of the company's stock valued at $328,000 after acquiring an additional 8,601 shares during the period. Finally, Graham Capital Management L.P. acquired a new stake in shares of Delcath Systems during the fourth quarter valued at approximately $123,000. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems Stock Up 5.4%

NASDAQ DCTH traded up $0.87 on Thursday, reaching $17.06. The company had a trading volume of 670,744 shares, compared to its average volume of 376,619. The stock's 50 day moving average is $13.20 and its 200-day moving average is $13.07. The stock has a market cap of $594.13 million, a price-to-earnings ratio of -12.64 and a beta of 0.72. Delcath Systems, Inc. has a 52 week low of $6.33 and a 52 week high of $18.23.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). The business had revenue of $19.80 million during the quarter, compared to analyst estimates of $16.83 million. Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. As a group, analysts forecast that Delcath Systems, Inc. will post -0.79 EPS for the current year.

Analyst Upgrades and Downgrades

DCTH has been the topic of several research reports. HC Wainwright reiterated a "buy" rating and issued a $29.00 price objective (up previously from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Wall Street Zen upgraded shares of Delcath Systems from a "buy" rating to a "strong-buy" rating in a research note on Saturday, May 24th. Four investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Delcath Systems has a consensus rating of "Buy" and a consensus target price of $24.00.

Delcath Systems Company Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.